Navigation Links
International study finds lower-dose IUDs are safe and effective
Date:12/5/2013

LOS ANGELES (Dec. 5, 2013) In a finding that could expand the use of one of the most effective forms of birth control, two intrauterine contraceptive systems that had lower doses of the contraceptive hormone, levonorgestrel, were found to be safe and effective in preventing pregnancies, according to an international study that included researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed).

The study, published in the December issue of the journal, Obstetrics & Gynecology, noted that the currently available higher-dose intrauterine contraceptive system has increased in popularity since its introduction in the U.S. in 2001 because of its safety, effectiveness and convenience: It doesn't require a woman to take a pill or take any specific actions immediately prior to intercourse.

But a recent survey found 60% of physicians rarely prescribe IUDs for women who have not borne children. In many European countries, they're only prescribed for women who have completed their families. Another recent study in U.S. family planning clinics found placement of the higher-dose intrauterine contraceptive systems failed in 19% of women who had not borne children.

The lower-dose intrauterine contraceptive systems are smaller than the higher-dose systems and, the study found, they are easier to use in women who have not delivered a child or have delivered only by cesarean section. Researchers at 138 centers across 11 countries tested the devices in nearly 3,000 women and rated placement of the smaller devices as "easy" in 90% of the women.

"By demonstrating the safety and efficacy of low-dose intrauterine contraceptive devices, this study will help expand the contraceptive options available to women who have not had children before," said Anita Nelson, MD, an LA BioMed lead researcher and corresponding author of the study. "Additionally, a lower dose system may be preferable to women who are seeking to reduce their exposure to synthetic hormones."

The study tested two intrauterine contraceptive systems: one with 13.5 milligrams of levonorgestrel and another with 19.5 milligrams. It found both to be highly effective and well-tolerated over a three-year period. The currently available higher-dose intrauterine contraceptive system has 52 milligrams of levonorgestrel.


'/>"/>

Contact: Laura Mecoy
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. International breast health global summit will focus on supportive care and quality of life
2. International conference to explore health of descendants of transatlantic slave trade
3. Kessler Foundation researchers present at first International Congress on Cognition in MS
4. Internationally known expert in ovarian cancer to be honored at the ASCO Annual Meeting
5. Nobel laureate to keynote international pharmaceutical conference at URI
6. International Nanomedicine Conference bound for Sydney: July 2-4, 2012
7. June 2012 marks a milestone for International Urogynecology Associates as Dr. Robert D. Moore and Dr. John R. Miklos perform their 24th Neovagina Surgery in 24 months
8. Heavy Duty Alternators and Starters Expert Elreg Distributors Ltd. Meets Needs of International Market with Launch of Spanish Website
9. The US Drug Watchdog Now Urges Plaintiffs Law Firms Worldwide To Contact Them About A Possible International Effort To Help Victims Of Defective Drugs Or Medical Devices
10. RMAX International to donate Recuper8 - a free, health - restoring program to Everyone in Uniform
11. International symposium on veterinary rehabilitation and physical therapy to be held in Vienna
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to take ... an inventor from Austin, Texas, has identified a solution. , She developed a prototype ... restricted lighting. As such, it eliminates the need to turn on a light when ...
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
Breaking Medicine Technology: